August 13, 2025

To
The Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

Scrip Symbol: COHANCE

To
The Department of Corporate Services,
BSE Limited
25th floor, P. J. Towers,
Dalal Street, Mumbai – 400 001

Scrip Code – 543064

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Completion of USFDA Inspection

We would like to inform you that the United States Food and Drug Administration (USFDA) has completed a Good Manufacturing Practices (GMP) inspection at our Finished Dosage Formulations Manufacturing Facility (FDF Unit-I) located in Nacharam, Hyderabad. The inspection was conducted from August 4, 2025 to August 12, 2025 excluding the weekend of August 9 and 10, 2025.

Following the inspection, the Company has received a Form 483 from the USFDA with 06 observations. These are predominantly procedural in nature. We are in the process of reviewing the observations in detail and are preparing a comprehensive response to be submitted to the agency within the stipulated timeframe.

We remain committed to maintaining the highest standards of quality and regulatory compliance in all our operations and will continue to ensure the manufacture and supply of high-quality pharmaceutical products for global markets.

This is for your information and record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)
KUNDAN KUMAR JHA
Digitally signed by KUNDAN KUMAR JHA
Date: 2025.08.13 22:55:54 +05'30'
Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal